Exiqon generated revenue of DKK 30 million, of which product sales amounted to DKK 21 million. Operating expenses amounted to DKK 81 million, and the loss for the period totalled DKK 47 Million. Exiqon today announces its intention to acquire privately held Oncotech Inc., a diagnostic company, in a separate announcement
Attachments
